Modern therapy of psoriasis from the point of view of systemic inflammation: experience of using the drug Efleira
- Авторлар: Merzlikina N.A.1, Svechnikova E.V1,2, Zhufina S.E1
-
Мекемелер:
- Polyclinic No. 1 of the Administrative Department of the President of the Russian Federation
- Novosibirsk State Medical University
- Шығарылым: Том 28, № 8 (2021)
- Беттер: 34-41
- Бөлім: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/313201
- DOI: https://doi.org/10.18565/pharmateca.2021.8.34-41
- ID: 313201
Дәйексөз келтіру
Ашық рұқсат
Рұқсат берілді
Аннотация
The article discusses clinical cases of patients with moderate and severe plaque psoriasis, psoriasis with involvement of sensitive area such as the scalp and nails, as well as with the presence of psoriatic arthritis. The purpose of this article is to evaluate the effectiveness of therapy for moderate-to-severe plaque psoriasis, psoriasis with involvement of sensitive area, as well as psoriasis with concomitant psoriatic arthritis with the new original IL-17 inhibitor netakimab (Efleira®). The experience obtained and presented in this review on the example of 4 clinical cases shows good results of therapy with the new original IL-17 inhibitor netakimab (Efleira®) not only in terms of assessing the skin status, but also in terms of a beneficial effect on the processes of systemic inflammation in psoriasis.
Негізгі сөздер
Толық мәтін
Авторлар туралы
Natalya Merzlikina
Polyclinic No. 1 of the Administrative Department of the President of the Russian Federation
Email: natalya.pryahina90@mail.ru
Dermatovenerologist, Department of Dermatovenereology and Cosmetology Moscow, Russia
E. Svechnikova
Polyclinic No. 1 of the Administrative Department of the President of the Russian Federation; Novosibirsk State Medical UniversityMoscow, Russia
S. Zhufina
Polyclinic No. 1 of the Administrative Department of the President of the Russian FederationMoscow, Russia
Әдебиет тізімі
- Федеральные клинические рекомендации по ведению больных псориазом. 2020
- Puig L. Cardiometabolic Comorbidities in Psoriasis and Psoriatic Arthritis. Int Mol Sci. 2018;19(1):58. doi: 10.3390/ijms19010058
- Бакулев А.Л., Фитилева Т.В., Новодережкина Е.А. и др. Псориаз: клинико-эпидемиологические особенности и вопросы терапии. Вестник дерматологии и венерологии. 2018;94(3):67-76
- Инструкция по медицинскому применению препарата Эфлейра. URL: http://grls.rosminzdrav.ru/grls.asp
Қосымша файлдар
